Heptares And Complix Raise Series B Funds To Advance Preclinical Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
GPCR-focused Heptares and the protein scaffold company Complix complete a seemingly rare event for European biotechs, a second round of VC funding.